BiotechTube

LY4395089 + Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Crohn Disease

Conditions

Crohn Disease

Trial Timeline

Apr 1, 2026 → Mar 1, 2028

NCT ID
NCT07483099

About LY4395089 + Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)

LY4395089 + Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC) is a phase 2 stage product being developed by Eli Lilly for Crohn Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07483099. Target conditions include Crohn Disease.

What happened to similar drugs?

12 of 20 similar drugs in Crohn Disease were approved

Approved (12) Terminated (4) Active (8)
✅Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
✅MirikizumabEli LillyApproved
✅Adalimumab Injection + ThiopurineAbbVieApproved
✅adalimumabAbbVieApproved
✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved
✅Infliximab + Prednisolone + AzathioprinePfizerApproved
✅Celebrex + placeboPfizerApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07483099Phase 2Recruiting

Competing Products

20 competing products in Crohn Disease

See all competitors
ProductCompanyStageHype Score
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
21
CT-P13 + RemicadeCelltrionPhase 3
40
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
39
Ustekinumab 45 mg + Ustekinumab 90 mgCelltrionPre-clinical
33
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
29
CT-P13 SC (Infliximab)CelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
CP-461Astellas PharmaPhase 2
35
UstekinumabSun PharmaceuticalPre-clinical
33
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
32
E6011 + PlaceboEisaiPhase 2
35
E6011 + PlaceboEisaiPhase 1
21
adalimumab + adalimumab + placeboEisaiPhase 2/3
38
adalimumabEisaiPhase 2/3
38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
40
MirikizumabEli LillyPhase 3
47
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
47
Mirikizumab + PlaceboEli LillyPhase 2
35
MirikizumabEli LillyPhase 3
44